Takeda, chasing Bristol Myers, unveils awaited TYK2 drug data
Bio Pharma Dive
MARCH 18, 2023
The eagerly anticipated results from a Phase 2 study in psoriasis show why the pharma paid $4 billion to buy the drug from startup Nimbus Therapeutics last year
Let's personalize your content